Eutropics is a biomarker discovery and clinical diagnostics, CLIA laboratory in Cambridge, MA. We provide a variety of ELISA and flow cytometry-based CLIA testing, including flow cytometry based functional and static assays that assess cancer patient biopsied cells for drug sensitivities We also provide ELISA based testing for serum markers including Human Anti-Mouse Antibodies (HAMA) including HAMAs against radionuclide antibody conjugates (RACs) for instance, Alpha-particle Therapies (TAT). Eutropics holds a radioactivity license to process biopsies from patients being treated with such therapies.
Our core capability lies in providing novel clinical diagnostic test platform that recognizes apoptotic potential of biopsied cancer cells, for instance Bcl-2 protein family dependencies. The information indicates the likelihood of patient response and can be used in selecting patients for clinical trials.
Our approach to assessing “BCL2 dependencies” using novel “PRIMAB” antibodies that measure the function of the Bcl-2 protein family. . The PRIMABS selectively bind to specific Bcl-2 family protein complexes. Readouts are detected on flow cytometry or IHC. . The complexes are known to correlate to cancer cell responsiveness to a wide range of apoptosis-inducing therapies, including BH3 mimetics.
CLIA technical and clinical validation of PRIMAB based or other biomarker tests are performed at Eutropics. Patient sample processing of fresh or viably frozen patient samples on flow cytometry and ELISA platforms is available. IHC services are also available.